Copilot says:

Here’s an enhanced overview of hydralazine’s anti-cancer research across various cancer types:

🧪 Mechanism Summary (All Types)

• DNA demethylating agent: hydralazine inhibits DNA methyltransferases (DNMTs), restoring tumor suppressor gene expression. [zealjournals.com], [annalsofoncology.org]
• Other mechanisms: includes anti-angiogenesis, inhibition of glutamate oxaloacetate transaminase 1, and pro-apoptotic actions. [zealjournals.com], [oncotarget.com]

🩸 Leukemic T‑Cells (In Vitro)

• Hydralazine provokes caspase-dependent apoptosis via the intrinsic/mitochondrial pathway, leading to DNA damage and reactive oxygen species buildup in p53-mutant Jurkat cells. [oncotarget.com]

🥇 Prostate Cancer

• In DU145 and other PCa cell lines, hydralazine downregulates DNMTs (DNMT1/3a/3b), demethylates promoters (e.g., GSTP1, BCL2, CCND2), reactivates tumor suppressors like AR and p21, induces apoptosis, DNA damage, and reduces invasiveness. [oncotarget.com], [mdpi.com], [mdpi.com]
• Shows synergy with epigenetic and androgen receptor therapies: panobinostat and enzalutamide in castration-resistant models. [mdpi.com], [mdpi.com]

🎀 Breast Cancer

• Combines with doxorubicin and disulfiram to enhance apoptosis and chemosensitivity in MCF-7 cells. [ctv.veeva.com]
• In a 2025 study, hydralazine + ATRA inhibited proliferation and hypoxia adaptation in MDA-MB-231 cells—hydralazine alone, though, could stimulate growth. [link.springer.com], [scienmag.com]

🧠 Glioblastoma

• Noted for inducing senescence by inhibiting the oxygen-sensing enzyme ADO, leading to halted glioblastoma cell growth in vitro. [sciencenewstoday.org], [foxnews.com], [medicaldialogues.in]

🧫 Colorectal Cancer

• Preclinical evidence (Ann Onc conference) suggests hydralazine may attenuate colorectal carcinoma, especially in microsatellite instability or chromosomal instability contexts. [annalsofoncology.org]
• Epidemiological data do not indicate increased colon cancer risk among hydralazine users; some long-term uncertainty remains. [link.springer.com], [synapse.mskcc.org]

👩‍⚕️ Cervical Cancer (Clinical Trials)

• Multiple clinical trials combining hydralazine + valproate with cisplatin-based chemotherapy or chemoradiation:
  • Phase I/II: cervical tumor biopsies showed DNA promoter demethylation and gene reactivation. [scilit.com]
  • Phase II: in 17 patients with stage IIIB disease—90% clinical complete response, acceptable safety. [trial.medpath.com], [ichgcp.net]
  • Phase III: randomized trial showed improved progression-free survival from ~6 to ~10 months when epigenetic therapy added to cisplatin/topotecan. [link.springer.com], [clinicaltrials.gov]

🧬 Hematologic Neoplasms (Population & Preclinical)

• Taiwanese cohort (2000–2015) found long‑term hydralazine users had lower incidence of hematologic cancers—lymphoid, myeloid leukemias, and multiple myeloma. [frontiersin.org], [journals.plos.org]
• Leukemic T-cell in vitro apoptosis noted above. [oncotarget.com]

⚠️ Summary Table

Hydralazine shows broad preclinical efficacy across multiple cancer types via DNA demethylation, apoptosis, senescence, and combination therapy synergies. Its most advanced clinical data exist in cervical cancer, where epigenetic combinations have meaningfully improved outcomes.